Scholarlink

<p>Research on the comprehensive integration of clinical and genomic characteristics in patients with core binding factor acute myeloid leukemia (CBF-AML) is limited. Clinical and genomic data from consecutive patients with CBF-AML were reviewed. A Cox regression model was used to identify the variables associated with event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). A total of 346 CBF-AML patients (211 with <i>RUNX1::RUNX1T1</i> and 135 with <i>CBFB::MYH11</i>) were included in this study. In the <i>RUNX1::RUNX1T1</i> cohort, multivariate analyses revealed that <i>KDM6A</i> mutations were significantly associated with poor RFS (hazard ratio = 3.1 [1.4, 7.1], <i>p</i> = 0.007) and OS (HR = 11.5 [3.6, 37.0], <i>p</i> &lt; 0.001); <i>FLT3</i>-TKD mutations, poor OS (HR = 4.9 [1.7, 14.3], <i>p</i> = 0.004); <i>KIT</i> mutation VAF &gt; 25%, poor RFS (<i>KIT</i><sup>wt</sup> as ref, HR = 2.5 [1.1, 5.3], <i>p</i> = 0.022); <i>ASXL1</i> mutations, favorable EFS (HR = 0.4 [0.2, 0.9], <i>p</i> = 0.016) and OS (HR = 0.2 [0.03, 0.8], <i>p</i> = 0.028). In the <i>CBFB::MYH11</i> cohort, multivariate analyses revealed that a high mutation burden was significantly associated with inferior OS (HR = 1.4 [1.1, 1.8], <i>p</i> = 0.018); <i>FLT3</i>-ITD mutations, inferior OS (HR = 6.8 [1.3, 36.0], <i>p</i> = 0.024). In addition, increasing age, nonintensive chemotherapy, and high MRD levels predict poor outcomes in the <i>RUNX1::RUNX1T1</i> cohort. In addition to the adverse impact of high <i>KIT</i> mutation burden and <i>FLT3</i>-ITD or <i>FLT3</i>-TKD mutations on prognosis in CBF-AML, <i>KDM6A</i> mutations predicted poor outcomes in patients with <i>RUNX1::RUXN1T1</i>; however, <i>ASXL1</i> mutations, favourable outcomes; high mutation burden, poor outcomes in those with <i>CBFB::MYH11</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月10日

查看全文
  • Shunjie Yu,
  • Sen Yang,
  • Lijuan Hu,
  • Wenbing Duan,
  • Ting Zhao,
  • Yazhen Qin,
  • Yazhe Wang,
  • Yueyun Lai,
  • Hongxia Shi,
  • Feifei Tang,
  • Yuqian Sun,
  • Jinsong Jia,
  • Jing Wang,
  • Shengye Lu,
  • Qiang Fu,
  • Hao Jiang,
  • Lanping Xu,
  • Yu Wang,
  • Xiaohui Zhang,
  • Xiaojun Huang,
  • Qian Jiang

摘要

Research on the comprehensive integration of clinical and genomic characteristics in patients with core binding factor acute myeloid leukemia (CBF-AML) is limited. Clinical and genomic data from consecutive patients with CBF-AML were reviewed. A Cox regression model was used to identify the variables associated with event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS). A total of 346 CBF-AML patients (211 with RUNX1::RUNX1T1 and 135 with CBFB::MYH11) were included in this study. In the RUNX1::RUNX1T1 cohort, multivariate analyses revealed that KDM6A mutations were significantly associated with poor RFS (hazard ratio = 3.1 [1.4, 7.1], p = 0.007) and OS (HR = 11.5 [3.6, 37.0], p < 0.001); FLT3-TKD mutations, poor OS (HR = 4.9 [1.7, 14.3], p = 0.004); KIT mutation VAF > 25%, poor RFS (KITwt as ref, HR = 2.5 [1.1, 5.3], p = 0.022); ASXL1 mutations, favorable EFS (HR = 0.4 [0.2, 0.9], p = 0.016) and OS (HR = 0.2 [0.03, 0.8], p = 0.028). In the CBFB::MYH11 cohort, multivariate analyses revealed that a high mutation burden was significantly associated with inferior OS (HR = 1.4 [1.1, 1.8], p = 0.018); FLT3-ITD mutations, inferior OS (HR = 6.8 [1.3, 36.0], p = 0.024). In addition, increasing age, nonintensive chemotherapy, and high MRD levels predict poor outcomes in the RUNX1::RUNX1T1 cohort. In addition to the adverse impact of high KIT mutation burden and FLT3-ITD or FLT3-TKD mutations on prognosis in CBF-AML, KDM6A mutations predicted poor outcomes in patients with RUNX1::RUXN1T1; however, ASXL1 mutations, favourable outcomes; high mutation burden, poor outcomes in those with CBFB::MYH11.